A Novel Herbal Medicine for Dyslipidemia: Assessments in Experimental Models

Table 5

Effects of GANMO on lipid levels in Poloxamer 407-induced dyslipidemia after 1 week of treatment.

Groups	n	Serum lipid levels ( ± SD)
		TG (mmol/L)	TC (mmol/L)	HDL-C (mmol/L)	Non-HDL-C (mmol/L)
Model group	10	6.29 ± 1.24	6.91 ± 0.92	1.53 ± 0.13	5.38 ± 0.88
Atorvastatin (100 mg/kg)	10	6.50 ± 1.92	4.70 ± 1.04^ΔΔΔ (↓ 32.0%)	1.63 ± 0.19 (↑ 6.5%)	3.07 ± 1.08^ΔΔΔ (↓ 42.9%)
GANMO (30.2 g/kg)	10	4.61 ± 1.52^Δ (↓ 26.7%)	5.15 ± 0.68^ΔΔΔ (↓ 25.5%)	1.74 ± 0.15^ΔΔ (↑ 13.7%)	3.41 ± 0.77^ΔΔΔ (↓ 36.6%)
GANMO (90.6 g/kg)	10	3.78 ± 0.72^ΔΔΔ (↓ 39.9%)	5.04 ± 1.04^ΔΔΔ (↓ 27.1%)	1.71 ± 0.21^Δ (↑ 11.8%)	3.33 ± 0.93^ΔΔΔ (↓ 38.1%)

Note: statistical analysis was done with t-test and ANOVA test, and was considered to be statistically significant; : and compared with the control group; ^{Δ, ΔΔ, ΔΔΔ}: , , and compared with the model group.